Sigyn Therapeutics, Inc.
SIGY
$2.76
-$0.99-26.40%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.57% | 12.17% | 5.36% | 25.35% | 15.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.21% | -5.02% | 2.61% | 24.84% | 23.44% |
| Operating Income | 11.21% | 5.02% | -2.61% | -24.84% | -23.44% |
| Income Before Tax | -3.71% | 8.77% | 19.43% | -4.30% | -1.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.71% | 8.77% | 19.43% | -4.30% | -1.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.71% | 8.77% | 19.43% | -4.30% | -1.45% |
| EBIT | 11.21% | 5.02% | -2.61% | -24.84% | -23.44% |
| EBITDA | 11.09% | 4.88% | -2.82% | -25.17% | -23.76% |
| EPS Basic | 15.65% | 21.66% | 32.39% | 15.68% | 18.10% |
| Normalized Basic EPS | 22.35% | 31.54% | 39.53% | 13.03% | 15.29% |
| EPS Diluted | 15.64% | 21.50% | 32.16% | 15.57% | 18.39% |
| Normalized Diluted EPS | 22.35% | 31.54% | 39.53% | 13.03% | 15.29% |
| Average Basic Shares Outstanding | 25.88% | 22.19% | 21.13% | 21.82% | 23.05% |
| Average Diluted Shares Outstanding | 25.88% | 22.19% | 21.13% | 21.82% | 23.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |